Publications
-
Loupakis F; Stein A; Ychou M; Hermann F; Salud A; Österlund P
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
TARGETED ONCOLOGY 11 293-308. .
-
Porcel, JM; Esquerda, A; Martinez-Alonso, M; Bielsa, S; Salud, A
Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers A Predictive Multivariate Model
Medicine 95 -. .
-
Sastre J; Díaz-Beveridge R; García-Foncillas J; Guardeño R; López C; Pazo R; Rodriguez-Salas N; Salgado M; Salud A; Feliu J
Clinical guideline SEOM: hepatocellular carcinoma
CLINICAL & TRANSLATIONAL ONCOLOGY 17 988-995. .
-
Fernandez-Martos C; Garcia-Albeniz X; Pericay C; Maurel J; Aparicio J; Montagut C; Safont MJ; Salud A; Vera R; Massuti B; Escudero P; Alonso V; Bosch C; Martin M; Minsky BD
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
ANNALS OF ONCOLOGY 26 1722-1728. .
-
Porcel JM; Palma R; Bielsa S; Esquerda A; Gatius S; Matias-Guiu X; Salud A
TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions
RESPIROLOGY 20 831-833. .
-
Porcel JM; Gasol A; Bielsa S; Civit C; Light RW; Salud A
Clinical features and survival of lung cancer patients with pleural effusions
RESPIROLOGY 20 654-659. .
-
Garcia-Alfonso P; Chaves M; Muñoz A; Salud A; García-Gonzalez M; Grávalos C; Massuti B; González-Flores E; Queralt B; López-Ladrón A; Losa F; Gómez MJ; Oltra A; Aranda E
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
Bmc Cancer 15 327-327. .
-
Porcel JM; Hernández P; Martínez-Alonso M; Bielsa S; Salud A
Accuracy of Fluorodeoxyglucose-PET Imaging for Differentiating Benign From Malignant Pleural Effusions A Meta-analysis
Chest 147 502-512. .
-
Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
PLOS ONE 10 -. .
-
Fernandez-Plana J; Pericay C; Quintero G; Alonso V; Salud A; Mendez M; Salgado M; Saigi E; Cirera L
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
Bmc Cancer 14 865-865. .
-
Fernandez-Martos C; Brown G; Estevan R; Salud A; Montagut C; Maurel J; Safont MJ; Aparicio J; Feliu J; Vera R; Alonso V; Gallego J; Martin M; Pera M; Sierra E; Serra J; Delgado S; Roig JV; Santos J; Pericay C
Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial
Oncologist 19 1042-1043. .
-
Gomez-Martín, C.; Lopez-Rios, F.; Aparicio, J.; Barriuso, J.; García-Carbonero, R.; Pazo, R.; Rivera, F.; Salgado, M.; Salud, A.; Vázquez-Sequeiros, E.; Lordick, F.
A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
CANCER LETTERS 351 30-40. .
Projects
- Ajuts per a la contractació de personal investigador novell (FI)
- Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
- Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
- UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
